Insights & Guides

GLP-1 Weight Loss Blog

Expert insights on GLP-1 medications, insurance coverage, clinic comparisons, and weight loss tips.

medications

The Wegovy Pill Is Here: How It Compares to Injections in 2026

Novo Nordisk launched the first oral GLP-1 for weight loss in 2026. How the Wegovy pill compares to injections on cost, results, and convenience.

February 12, 2026 Read more →
medications

Saxenda vs Ozempic: Which Is Better for Weight Loss?

Comparing liraglutide (Saxenda) to semaglutide (Ozempic/Wegovy) for weight loss: effectiveness, cost, injection frequency, and side effects.

February 9, 2026 Read more →
medications

Switching from Ozempic to Mounjaro: What to Expect

Considering a switch from semaglutide to tirzepatide? Here's how the transition works, dose equivalencies, and what patients typically experience.

February 6, 2026 Read more →
medications

Compounded Semaglutide vs Brand-Name Wegovy: What You Need to Know

Compounded semaglutide costs a fraction of Wegovy, but is it safe and effective? Here's how they compare on quality, cost, and legality.

February 2, 2026 Read more →
medications

GLP-1 Medications for Type 2 Diabetes vs Weight Loss: Key Differences

GLP-1 drugs treat both type 2 diabetes and obesity, but dosing, insurance coverage, and FDA approvals differ significantly between the two uses.

January 25, 2026 Read more →
medications

Understanding GLP-1 Weight Loss: How Semaglutide and Tirzepatide Work

A science-based explanation of how GLP-1 receptor agonists cause weight loss. How semaglutide and tirzepatide work and why they are effective.

January 24, 2026 Read more →
medications

Zepbound vs Mounjaro: Understanding Tirzepatide Options

Zepbound and Mounjaro both contain tirzepatide but are approved for different conditions. Compare their dosing, cost, and insurance coverage.

January 20, 2026 Read more →
medications

Ozempic vs Wegovy: What's the Difference?

Both contain semaglutide, but they're FDA-approved for different purposes. Here's what you need to know before choosing between them.

January 15, 2026 Read more →